Yongman Kim, PhD

Chief Scientific Officer, Chief Innovation Officer

Dr. Kim has over 14 years of experience in the industry of cellular therapeutics. Prior to working for NKMAX, he served as the GMP and R&D Center Director for Pharmicell Co., Ltd, a well-known Korean Stem Cell Biopharmaceutical Company, where he successfully obtained the first stem cell therapy KFDA approval in Korea.

Prior to working in the Industry, Dr. Kim was a research Professor at Wonkwang University School of Medicine. He has been a visiting Fellow for the Genetic Pharmacology Unit in NINDS, the Neurobiological branch of the National Institute of Health. He had his Post-Doc. at the Department of Immunology at the Korea Research Institute of Bioscience and Biotechnology. He earned his PhD in Cell Biology from Chungnam National University in Korea.